HC Wainwright Reaffirms Buy Rating for PHAT
HC Wainwright maintains its buy rating for PHAT, setting a $26 price target, a 149.28% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating for PHAT on June 17, 2026, with a price target of $26.
- HC Wainwright's $26 price target implies 149.28% upside from Phathom Pharmaceuticals, Inc.'s ($PHAT) current $10.43 share price.
- Shares of PHAT traded at $10.43, with institutional investors like BlackRock increasing their holdings.
- Insider transactions included substantial buying activity by Asit Parikh in May 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, HC Wainwright reiterated its buy rating for PHAT, setting a price target of $26. This reaffirmation by analyst Matthew Caufield underscores confidence in PHAT's potential upside, as the stock traded at $10.43 on the market.
Other Institutional Activity in PHAT
Several institutional investors have shown interest in PHAT. BlackRock, Inc. increased its holdings by 506,448 shares, bringing its total to 4,061,996 shares valued at approximately $45.1 million. Invesco Ltd. also added 401,614 shares, resulting in a total of 4,322,060 shares worth about $48 million. Millennium Management LLC made a significant increase, adding 1,940,729 shares to reach a total of 4,022,909 shares valued at about $44.7 million.
Phathom Pharmaceuticals, Inc. Stock Up 13.6%
Shares of PHAT traded at $10.43. The stock has seen various levels of institutional interest, as reflected in recent trading activity and analyst ratings.
Insider Buying and Selling at Phathom Pharmaceuticals, Inc.
Recent insider activity at PHAT includes multiple transactions by Asit Parikh. On May 22, 2026, Parikh bought and sold 28,000 shares. Earlier, on May 20, 2026, Parikh purchased 17,500 shares at an average price of $4.95. Additionally, on May 19, 2026, both Parikh and James Topper acquired 24,122 shares each.
Analysts Set New Price Targets
On June 17, 2026, HC Wainwright & Co. reiterated its buy rating with a $26 price target. Earlier, on March 27, 2026, Barclays upgraded its rating to buy with an $18 target. Guggenheim maintained a buy rating with a $25 target on February 27, 2026. The consensus among analysts is generally positive, with a majority recommending a buy.
Bottom Line
HC Wainwright's reaffirmation of its buy rating for PHAT with a $26 target highlights ongoing confidence in the company's future prospects. Institutional investors like BlackRock and Millennium Management have increased their positions, indicating a broader interest in the stock. Insider buying activity further adds to the narrative of potential growth, although investors should remember that these insights are based on past filings and may not represent current positions.
Get Phathom Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PHAT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.